{
  "docId": "019de070-c58c-706c-98f1-9eec26811648",
  "docSlug": "2a1e5b2d3a1cb25fe50abb3e75ae9bdf",
  "documentTitle": "Alkermes | Investor Day Presentation Deck | 144 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 36,
  "pageCount": 132,
  "prevPage": 35,
  "nextPage": 37,
  "slideType": "executive_summary",
  "function": "establish_context",
  "density": "overcrowded",
  "nDataPoints": 1,
  "notes": "The slide uses a 2x2-style grid layout to contrast commercial products with development pipeline candidates.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de070-c58c-706c-98f1-9eec26811648/36",
  "deckHref": "/decks/019de070-c58c-706c-98f1-9eec26811648",
  "deckJsonHref": "/decks/019de070-c58c-706c-98f1-9eec26811648.json",
  "deckAnchorHref": "/decks/019de070-c58c-706c-98f1-9eec26811648#slide-36",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.82
      },
      "kind": "callout",
      "text": "Focus on Profitability: Focus on driving cost efficiencies and operating leverage while investing in the long-term growth of high-potential commercial and development-stage products",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c79cd818-ea68-4c0d-a5a4-3f19151ef07f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.65,
        "x": 0.32,
        "y": 0.22
      },
      "kind": "image",
      "text": "Vivitrol, Aristada, Lybalvi, Vumerity logos",
      "attrs": null,
      "subkind": "logo-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "99519119-2fca-4392-9360-a2d204f9c4d1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.25,
        "x": 0.05,
        "y": 0.55
      },
      "kind": "list",
      "text": "Pipeline of novel development candidates designed to target significant unmet needs",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "65048c1a-3f0d-41e3-b7e0-2eabad2f5ef9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.25,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "list",
      "text": "Significant, diverse revenues driving >$1B topline and positioned for growth",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "98015400-8965-4192-b44d-d8ffb70df42b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.25,
        "x": 0.65,
        "y": 0.45
      },
      "kind": "paragraph",
      "text": "Neuroscience: ALKS 1140 (IND-enabling, Neurodegenerative), Orexin 2R Agonist (Preclinical, Narcolepsy)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5fba857f-b2db-48b6-8d3c-8988326adedb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.25,
        "x": 0.35,
        "y": 0.45
      },
      "kind": "paragraph",
      "text": "Oncology: Nemvaleukin alfa (Phase 2, Advanced solid tumors), IL-12 (Preclinical, Advanced solid tumors)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8cbb71e2-a699-485e-a37d-c53c3866734a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.05,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "*LYBALVI NDA under FDA review; PDUFA June 1, 2021",
      "attrs": {
        "numbered": true
      },
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2578f038-5a21-4e11-b72d-579f2f7bba0a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Diversified Biopharmaceutical Company With Proven Drug Development and Commercialization Capabilities",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3441e97b-1bc0-4a2a-a979-f5d573dd30d5",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "matrix-2x2",
      "slug": null,
      "matchId": "87a47eef-f857-4e97-b763-7d53df80e4b3",
      "evidence": "The slide organizes information into a grid comparing commercial vs pipeline and oncology vs neuroscience.",
      "confidence": 0.7
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}